Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics
RARE Price/Volume Stats
| Current price | $42.31 | 52-week high | $54.98 |
| Prev. close | $42.87 | 52-week low | $31.52 |
| Day low | $42.21 | Volume | 886,829 |
| Day high | $44.20 | Avg. volume | 764,026 |
| 50-day MA | $48.05 | Dividend yield | N/A |
| 200-day MA | $42.18 | Market Cap | 3.48B |
RARE Stock Price Chart Interactive Chart >
Ultragenyx Pharmaceutical Inc. (RARE) Company Bio
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.
Latest RARE News From Around the Web
Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.
13 Most Promising Future Stocks To Buy According To Hedge FundsIn this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. Investing, for the most part, is all […] |
Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid ClaimsThe Justice Department alleges Ultragenyx paid for free genetic tests for patients, and bought test results, to induce prescriptions of its drug Crysvita. |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 30,325 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Em |
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterolNOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hyperchole |
Wells Fargo starts Ultragenyx coverage with overweight ratingMore on Ultragenyx Pharmaceutical |
RARE Price Returns
| 1-mo | -10.68% |
| 3-mo | -2.60% |
| 6-mo | 26.49% |
| 1-year | 3.83% |
| 3-year | -61.08% |
| 5-year | -34.33% |
| YTD | -11.52% |
| 2023 | 3.22% |
| 2022 | -44.90% |
| 2021 | -39.25% |
| 2020 | 224.12% |
| 2019 | -1.77% |
Continue Researching RARE
Want to do more research on Ultragenyx Pharmaceutical Inc's stock and its price? Try the links below:Ultragenyx Pharmaceutical Inc (RARE) Stock Price | Nasdaq
Ultragenyx Pharmaceutical Inc (RARE) Stock Quote, History and News - Yahoo Finance
Ultragenyx Pharmaceutical Inc (RARE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...